Literature DB >> 17457190

Supratarsal triamcinolone injection in the treatment of superior limbic keratoconjunctivitis.

Ying-Cheng Shen1, Chun-Yuan Wang, Hin-Yeung Tsai, Yi-Fen Lee.   

Abstract

PURPOSE: To evaluate the efficacy of supratarsal triamcinolone injection in the treatment of superior limbic keratoconjunctivitis (SLK).
METHODS: Forty eyes of 20 patients were diagnosed with SLK. All eyes with long-standing severe ocular irritation unresponsive to topical steroid and artificial tears were treated with supratarsal triamcinolone injection in addition to ongoing treatment of dry eye. Objective tarsal conjunctiva inflammation, bulbar conjunctiva, cornea staining, and subjective symptom gradings were performed before and after 2 weeks of therapy. All patients underwent laboratory evaluations of underlying systemic abnormalities.
RESULTS: All 40 eyes responded well to treatment and had long-term (average, 7.8 months) improvement of irritation and dry sensation and improvement of inflammation and staining of conjunctiva and cornea. Fourteen patients (70%) had associated autoimmune diseases. There were no irreversible complications related to this therapy.
CONCLUSIONS: Supratarsal triamcinolone injection effectively and rapidly resolved symptoms and signs associated with SLK. It is helpful as primary or adjunctive therapy for SLK.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17457190     DOI: 10.1097/ICO.0b013e318030d230

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  4 in total

Review 1.  A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain.

Authors:  Harrison Dermer; Daniella Lent-Schochet; Despoina Theotoka; Christian Paba; Abdullah A Cheema; Ryan S Kim; Anat Galor
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

2.  Supratarsal injection of triamcinolone acetonide and childhood allergic keratoconjunctivitis.

Authors:  Sonia Zaouali; Rim Kahloun; Sonia Attia; Bechir Jelliti; Manel Trigui; Salim Ben Yahia; Riadh Messaoud; Moncef Khairallah
Journal:  Int Ophthalmol       Date:  2012-02-14       Impact factor: 2.031

3.  Efficacy and safety of 0.1% lodoxamide for the long-term treatment of superior limbic keratoconjunctivitis.

Authors:  Alejandro Rodriguez-Garcia; Yolanda Macias-Rodriguez; Jose M Gonzalez-Gonzalez
Journal:  Int Ophthalmol       Date:  2017-06-10       Impact factor: 2.031

4.  Extensive superior limbic keratoconjunctivitis in Graves' disease: case report and mini-review of the literature.

Authors:  Elias Chelala; Hala El Rami; Ali Dirani; Henry Fakhoury; Ali Fadlallah
Journal:  Clin Ophthalmol       Date:  2015-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.